Get the Stockscreener App
1.57
2.48%
-0.04
After Hours:
1.53
-0.04
-2.55%
Atossa Therapeutics Inc stock is currently priced at $1.57, with a 24-hour trading volume of 809.97K.
It has seen a -2.48% decreased in the last 24 hours and a +16.30% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.60 pivot point. If it approaches the $1.55 support level, significant changes may occur.
Previous Close:
$1.61
Open:
$1.6
24h Volume:
809.97K
Market Cap:
$197.44M
Revenue:
-
Net Income/Loss:
$-30.09M
P/E Ratio:
-6.28
EPS:
-0.25
Net Cash Flow:
$-20.96M
1W Performance:
+5.37%
1M Performance:
+16.30%
6M Performance:
+130.88%
1Y Performance:
+121.13%
1D Range:
$1.55
$1.60
52W Range:
$0.62
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206-588-0256
Address
107 Spring Street, Seattle, WA
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($0.05) Per Share (NASDAQ:ATOS) - Defense World
Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update - MarketBeat
MarketBeat
Brokers Issue Forecasts for Atossa Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ATOS) - MarketBeat
MarketBeat
Atossa Therapeutics (NASDAQ:ATOS) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
MarketBeat
Atossa Therapeutics gives final dose in breast cancer prevention study - Proactive Investors UK
Proactive Investors UK
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial - GlobeNewswire
GlobeNewswire
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Atossa Therapeutics Inc (ATOS) Net Income 2024
ATOS net income (TTM) was -$30.09 million for the quarter ending December 31, 2023, a -11.62% decrease year-over-year.
Atossa Therapeutics Inc (ATOS) Cash Flow 2024
ATOS recorded a free cash flow (TTM) of -$20.95 million for the quarter ending December 31, 2023, a -0.81% decrease year-over-year.
Atossa Therapeutics Inc (ATOS) Earnings per Share 2024
ATOS earnings per share (TTM) was -$0.24 for the quarter ending December 31, 2023, a -12.83% decline year-over-year.
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Former EVP, CFO, & Director |
Nov 15 '23 |
Sale |
0.65 |
50,000 |
32,500 |
55 |
About Atossa Therapeutics Inc
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
0.77%
1.20%
Cap:
|
Volume (24h):